Financing

#Biotech #Financing #mRNA #Seed funding

Biotech raises a €31.5m seed round to develop mRNA therapeutics

SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round.   The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated… Read More

#Business & Investment #News #Start-up Zone

Financing or funding
#Arthritis #Financing #Investment #Rheumatology #Spinout

Anaheim Bio launches with €40 million Series A financing

Alesta Therapeutics spin-out Anaheim Bio has launched with an oversubscribed €40 million Series A financing.  The company was formed in 2026 from programmes spun out of Alesta Therapeutics and is backed by Alesta’s former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV… Read More

#Business & Investment #News #Start-up Zone

#ALLOX #Artificial intelligence (AI) #Drug discovery #Financing #Seed funding

ALLOX closes $10.5m financing to scale allosteric discovery platform

ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.   The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC… Read More

#Business & Investment #News #Start-up Zone

#Artificial intelligence (AI) #Automation / robotics #Financing #Opentrons

Opentrons announces $40m Series E funding round

Opentrons Labworks has announced a $40 million Series E financing led by healthcare investor Avego, with additional investment from BroadOak Capital Partners.   Opentrons says it will use the capital to scale its robotics, software, and data infrastructure tools.  While AI is transforming how science is… Read More

#Business & Investment #News

Microbiome
#Financing #Microbiotica #Phase II trial #Ulcerative colitis (UC)

Microbiotica raises £36 million to advance into Phase II

Biopharma company Microbiotica has closed £36 million in Series C financing to support the advancement of its treatment for ulcerative colitis. The financing was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. All existing Series B investors… Read More

#Business & Investment #News

#Endocrinology #Financing #Immunology #OMass Therapeutics

OMass closes $310m oversubscribed financing round

Biotechnology company OMass Therapeutics has raised $310 million as part of an oversubscribed Series C financing round.  The funding will be used to support the advancement of the company’s lead programme into Phase II clinical development.   The company’s lead compound, OMS1620, is a potential… Read More

#Business & Investment #News

Remyelination
#Financing #Multiple sclerosis #Neurology #Neuroscience #Rewind Therapeutics

New financing supports Rewind’s GPR17 remyelination programme

Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS).  MS is characterised by damage to myelin, but there are no approved therapies… Read More

#News

University of Melbourne
#Financing #Radiopharmaceuticals #Spinout #Start-ups #University of Melbourne

Melbourne radiopharmaceuticals spinout launches with AUD$12 million

Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate.  The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:… Read More

#Business & Investment #News #Start-up Zone

Structure of the eye
#Breye Therapeutics #Financing #Ophthalmology #Retinal diseases

Breye raises €67.5 million for retinal disease therapies

Breye Therapeutics has closed an over-subscribed €67.5 million Series A financing round.   The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze… Read More

#Business & Investment #News

#Big Picture Bio #Combination therapy #Financing #Innovate UK #Oncology #Start-ups

Deep Science Ventures veterans launch Big Picture Bio

A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding.  Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how… Read More

#Business & Investment #News #Start-up Zone

#Cardiometabolic diseases #Financing #Investment #Revier Therapeutics

Revier launches into cardiometabolic disease market with €6m

Revier Therapeutics has closed a €6 ($6.9) million seed financing and the launch of its operations.   The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.   The financing was led by the KHAN… Read More

#Business & Investment #News

#Financing #Kynexis #Neuroscience #Phase II trial #Schizophrenia

Kynexis extends Series A to €97m to advance cognitive disorder drug

Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million).   The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures.   In… Read More

#Business & Investment #News

siRNA
#Financing #Oligonucleotide therapeutics #Ractigen Therapeutics #RNA #RNA Therapeutics #saRNA

Ractigen Therapeutics closes over $31 million financing 

Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, has closed a new financing round exceeding $31 million (over RMB 200 million).  The round was led by Guozhong Capital, with participation from IDG Capital, China Everbright Limited, Jolmo Capital, Win-Win Capital, and SND Financial… Read More

#News

#3D deep learning imaging #Deep learning #Drug discovery #Financing #Imaging #Qureight #Series B financing

Qureight closes $20 million Series B financing 

Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.  Existing investors Hargreave Hale… Read More

#News